Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Novo Nordisk
 More »

  • More Data Suggest Novo's IDegLira Improves Glycemic Control without...
    ... Data from the DUALT I and DUALT II trials demonstrate efficacy of IDegLira, a Combination of Two Novo Nordisk Medications. More Data Suggest Novo's IDegLira Improves Glycemic ...
    9-27-2013
  • Adimab Licenses Antibody Platform to GSK, Biogen Idec
    ... In addition to Biogen Idec and GSK, Adimab's partners include Merck, Roche, Novartis, Eli Lilly, Genentech, Novo Nordisk, Human Genome Sciences, Gilead, and Kyowa Hakko Kirin. ...
    7-26-2013
  • Novo Nordisk Tops GEN List of Top 25 Biotech Companies
    New Rochelle, NY, July 24, 2013-For the second year in a row Novo Nordisk (NYSE:NVO) ranked No. 1 on the Genetic Engineering & Biotechnology News list of the top 25 biotech ...
    7-25-2013
  • Top 25 Biotech Companies of 2013
    ... 777,707,877 shares * price $70.79) % Change: 42.9% Position on 2012 List: #2 #1. Novo Nordisk 2013 Market Cap: $85.335 billion (7/2: 535.0 million shares * price DKK 911.50) ...
    7-15-2013
  • Nudging Difficult-to-Express Proteins Along
    ... Dombkowski observed. A recent patent application, by DbD licensee Novo Nordisk, describes introduction of a disulfide linkage in growth hormone to make the molecule more resistant ...
    6-15-2013
  • Novo Acquires Anti-Infective Developer Xellia for $700M
    Carl-Åke Carlsson said in a statement. 3i and Xellia's other shareholders sold all their shares to Novo, which is also the major shareholder in Novo Nordisk, Novozymes, and Chr. ...
    5-21-2013
  • Novo Nordisk Reports Promising Phase III Results for Hemophilia...
    Novo Nordisk today reported positive results from its paradigm(tm)2 Phase III trial for N9-GP (glycopegylated recombinant factor IX), for hemophilia B patients. The multi-center ...
    5-17-2013
  • Emergent, Caisson Collaborating to Optimize Heparosan Drug Delivery...
    Emergent said that planning for this partnership was a year in the making, after Caisson signed a development and licensing deal worth up to $100 million with Novo Nordisk . ...
    5-1-2013
  • Genome Editing for R&D and Therapeutics
    ... They are also pursuing diabetes in collaboration with Novo Nordisk. "There is a huge market for companies wanting to model their test drugs. We are also utilizing our TALEN ...
    3-1-2013
  • Growing the Biobased Economy
    Not a single industrial biotech company was publicly traded. Novozymes was still to be spun out of Novo Nordisk. Dow Chemical was the most heavily and widely invested strategic ...
    2-21-2013
  • FDA Blocks Novo, Boosts Celgene
    FDA delivered bad news to Novo Nordisk and good news to Celgene in separate decisions Friday on applications for marketing new drugs. The agency threw a curve to Novo by insisting ...
    2-11-2013
  • Challenging the Limits of Protein Characterization
    ... They tell you basically what to do, but they don't tell you how to do it, nor when to do it, nor propose clear acceptance criteria." Where Is It? Researchers at Novo Nordisk use ...
    2-1-2013
  • Type 2 Diabetes Drugs Drive Sector Growth
    ... Novo Nordisk, one of the biggest suppliers of insulin, submitted an NDA in November for Tresiba® (degludec), which offers extended dosing but increases cardiovascular risks. ...
    2-1-2013
  • Novo Nordisk Diabetes Drugs Green-Lighted by EC
    The European Commission today granted Novo Nordisk approval across all 27 European Union member states for two new adult diabetes drugs-Tresiba® (insulin degludec) and Ryzodeg® ...
    1-22-2013
  • Eliminating Biological Change after Excision
    ... However, in a study by Professor Jesper Olsen's research group at the Center for Protein Research, Novo Nordisk Foundation, heat stabilization has been incorporated into their ...
    1-15-2013
  • More »

    Journal Articles

  • Clean Capitalism at Novo Nordisk
    Bill Ferguson
    Sustainability: The Journal of Record
    Clean Capitalism at Novo Nordisk Sustainability: The Journal of Record
  • Efficacy and Safety Performance of the Innovo ® Insulin Doser
    Niek K. Valk, Gerhard Cerny, Jochen Sieber, Lene Lytzen, Birgitte Berg
    Diabetes Technology & Therapeutics
    Efficacy and Safety Performance of the Innovo ® Insulin Doser Diabetes Technology & Therapeutics Innovo® (Novo Nordisk A/S, Hillerød, Denmark) is a new insulin injection system ...
  • Needle with a Novel Attachment Versus Conventional Screw-Thread...
    Birtha Hansen, Søren K. Lilleøre, Gitte Ter-Borch
    Diabetes Technology & Therapeutics
    Diabetes Technology & Therapeutics Abstract Background: NovoTwist® (Novo Nordisk A/S, Bagsværd, Denmark) is an insulin pen needle that features a novel attachment and detachment ...
  • A Prefilled Insulin Pen with a Novel Injection Mechanism and...
    Hans Hemmingsen, Marcus Niemeyer, Marianne Rye Hansen, Ditlef Bucher, Niels Bjerrum Thomsen
    Diabetes Technology & Therapeutics
    Diabetes Technology & Therapeutics Abstract Background: FlexTouch® (Novo Nordisk A/S, Bagsvaerd, Denmark) is a new prefilled insulin pen for people with diabetes, with a novel ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Balancing Family and Career for Women Ph.D.s

Which changes made to academic culture are most likely to encourage women researchers to stay?

Suggest a Poll